Business & Industry News Channel
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer's disease
Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA
Esketamine receives Breakthrough Therapy Designation from FDA for major depressive disorder with imminent risk for suicide
Amgen and Advaxis enter global cancer immunotherapies collaboration
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
Pfizer announces publication of new analysis showing long-term therapy with VYNDAQEL (tafamidis) slowed progression of rare neurodegenerative disease
Vonvendi, the first and only recombinant treatment for adults affected by von Willebrand disease, launches in the USA
More Articles ...
- GSK and Verily to establish Galvani Bioelectronics - a new company dedicated to the development of bioelectronic medicines
- Boehringer Ingelheim: Growth in all core businesses
- Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
- Pfizer aims to become industry leader in gene therapy with acquisition of Bamboo Therapeutics, Inc.
- Bristol-Myers Squibb reports second quarter financial results
- Merck receives Breakthrough Therapy Designation from FDA and PRIME status from EMA for investigational Ebola Zaire vaccine (V920)
- Roche delivers continued growth in the first half of 2016